2.12
前日終値:
$2.03
開ける:
$2.02
24時間の取引高:
6.09M
Relative Volume:
2.11
時価総額:
$349.62M
収益:
$101.21M
当期純損益:
$-569.00K
株価収益率:
-106.00
EPS:
-0.02
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
+10.99%
1か月 パフォーマンス:
-11.30%
6か月 パフォーマンス:
+171.79%
1年 パフォーマンス:
+78.15%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
CTMX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CTMX
Cytomx Therapeutics Inc
|
2.12 | 349.62M | 101.21M | -569.00K | -56.88M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-07-31 | 開始されました | Oppenheimer | Outperform |
2025-05-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
2025-04-14 | 再開されました | Piper Sandler | Overweight |
2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
2024-05-06 | アップグレード | Jefferies | Hold → Buy |
2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
2021-11-15 | 開始されました | BTIG Research | Buy |
2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
2021-03-29 | 開始されました | JP Morgan | Overweight |
2021-03-23 | アップグレード | Jefferies | Hold → Buy |
2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
2020-03-04 | 開始されました | Barclays | Equal Weight |
2019-11-20 | 開始されました | Guggenheim | Buy |
2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
2019-06-13 | 開始されました | Mizuho | Buy |
2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
2019-03-11 | 開始されました | Barclays | Overweight |
2018-11-26 | 開始されました | Piper Jaffray | Overweight |
2018-10-15 | 開始されました | Goldman | Neutral |
2018-09-13 | 開始されました | H.C. Wainwright | Buy |
2018-06-01 | 開始されました | SunTrust | Buy |
2018-01-05 | 開始されました | Citigroup | Buy |
2017-09-08 | 開始されました | Wedbush | Outperform |
2017-03-27 | 開始されました | H.C. Wainwright | Buy |
2017-03-02 | 開始されました | Instinet | Buy |
2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
What makes CytomX Therapeutics Inc. stock price move sharplyJuly 2025 Drop Watch & Risk Adjusted Swing Trade Ideas - beatles.ru
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - MSN
Is This the Dip to Buy in CytomX Therapeutics Inc.Breakout Watch & Expert Approved Trade Ideas - classian.co.kr
What institutional flow reveals about CytomX Therapeutics Inc.Buy Signal & Community Verified Watchlist Alerts - Newser
CytomX Therapeutics Inc. stock trend forecastGlobal Markets & Expert Curated Trade Setup Alerts - Newser
CytomX Therapeutics Inc. Stock Performance After Earnings: Historical InsightsPortfolio Gains Summary & AI Optimized Trading Strategy Guides - Newser
News impact scoring models applied to CytomX Therapeutics Inc.Weekly Trend Recap & Capital Efficient Trade Techniques - Newser
Intraday Charts Show Spike in CytomX Therapeutics Inc. ActivityGap Down & Advanced Swing Trade Entry Plans - sundaytimes.kr
Analyzing CytomX Therapeutics Inc. with multi timeframe chartsMarket Activity Recap & Technical Analysis for Trade Confirmation - Newser
Advanced analytics toolkit walkthrough for CytomX Therapeutics Inc.Gap Up & Free Technical Confirmation Trade Alerts - Newser
Is this a good reentry point in CytomX Therapeutics Inc.Portfolio Performance Summary & Weekly Watchlist of Top Performers - Newser
Identifying reversal signals in CytomX Therapeutics Inc.Weekly Profit Analysis & Weekly Market Pulse Alerts - Newser
Technical analysis overview for CytomX Therapeutics Inc. stockJuly 2025 Pullbacks & Long-Term Growth Plans - Newser
CytomX's High-Risk, High-Reward ADC Strategy: Can CX-2051 Overcome Safety Hurdles and Deliver Value? - AInvest
Published on: 2025-08-15 21:04:24 - sundaytimes.kr
CytomX to continue Phase I ADC trial despite patient death - Yahoo Finance
CytomX Therapeutics Soars 10.23% on Clinical Trial Progress - AInvest
Is CytomX Therapeutics Inc. stock poised for growth2025 Technical Overview & Community Consensus Picks - Newser
FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares Boosts Biotech Portfolio - AInvest
RSI Suggests Rebound May Be Near in CytomX Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Reports - metal.it
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event - MSN
Cancer patient dies in clinical trial, drugmaker's stock falls, but the study goes on - The Business Journals
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors - Barchart.com
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st
Slammed 26% CytomX Therapeutics, Inc. (NASDAQ:CTMX) Screens Well Here But There Might Be A Catch - 富途牛牛
Is CytomX Therapeutics Inc. reversing from oversold territory2025 Key Highlights & Community Verified Swing Trade Signals - Newser
What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World
CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com
Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛
CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus
CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria
CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener
CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study - TradingView
CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan
HC Wainwright Issues Pessimistic Outlook for CTMX Earnings - Defense World
Published on: 2025-08-13 07:49:54 - sundaytimes.kr
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Inc. Inches Above Key Support — Safe to HoldMarket Momentum Signal Generator Shows Trends - beatles.ru
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - NewsBreak: Local News & Alerts
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
Cytomx Therapeutics Inc (CTMX) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
大文字化:
|
ボリューム (24 時間):